Intestinal Trefoil Factor (ITF/TFF3)
Intestinal Trefoil Factor (TFF3) is a 59-amino acid trefoil peptide secreted by goblet cells that plays a central role in mucosal restitution and epithelial barrier maintenance throughout the gastrointestinal tract. It promotes rapid wound healing of the gut epithelium through motogenic signaling independent of cell proliferation, and is under investigation for oral formulations targeting inflammatory bowel disease and other GI barrier disorders.
Intestinal Trefoil Factor (ITF), also designated Trefoil Factor 3 (TFF3), is a 59-amino acid peptide belonging to the trefoil factor family of secretory proteins. It is constitutively expressed and secreted by goblet cells throughout the small and large intestine, where it functions as a key mediator of mucosal restitution — the rapid migration of epithelial cells to cover superficial wounds in the gastrointestinal lining.
Overview
TFF3 was first identified and characterized in the early 1990s as the intestinal member of the trefoil factor family, following the discovery of TFF1 (pS2) in gastric mucosa and TFF2 (spasmolytic polypeptide) in gastric neck cells. The trefoil factors share a conserved structural motif — the trefoil or P-domain — consisting of approximately 42-43 amino acids with three intramolecular disulfide bonds that create a characteristic three-looped cloverleaf topology. This domain renders trefoil peptides extraordinarily resistant to heat, acid, and enzymatic digestion, properties that are functionally critical for peptides operating in the proteolytically active environment of the gastrointestinal lumen.
TFF3 is the predominant trefoil peptide of the intestine. It is synthesized and secreted constitutively by goblet cells of the small intestine, colon, and rectum, and is co-packaged with mucin glycoproteins (MUC2) in secretory granules. Upon release, TFF3 integrates into the mucus gel layer overlying the epithelium, where it contributes to the viscoelastic properties of mucus and participates in mucosal defense. TFF3 expression is markedly upregulated at sites of mucosal injury — a phenomenon termed the "ulcer-associated cell lineage" — indicating its role as an acute-phase repair factor.
The peptide exists in both monomeric and dimeric forms. The TFF3 homodimer, linked by a seventh disulfide bond at Cys-57, is the predominant circulating and secreted form and displays higher biological activity in restitution assays than the monomer. TFF3 also forms heterodimers with IgG Fc-binding protein (FCGBP), a large mucin-associated glycoprotein, suggesting additional roles in mucus architecture and innate immune defense.
TFF3 knockout mice develop spontaneous colitis and exhibit dramatically impaired mucosal healing after chemical injury (DSS colitis), confirming TFF3 as essential for normal intestinal mucosal defense and repair. These observations have driven interest in recombinant TFF3 and TFF3-Fc fusion proteins as therapeutic agents for inflammatory bowel disease, radiation enteritis, and other conditions involving gut barrier breakdown.
Mechanism of Action
TFF3 promotes mucosal defense and repair through several interconnected mechanisms:
-
Motogenic signaling (restitution): TFF3 stimulates rapid epithelial cell migration across denuded basement membrane to reseal superficial mucosal wounds, a process called restitution. This occurs independently of cell proliferation and involves activation of MAPK/ERK signaling pathways and rearrangement of the actin cytoskeleton. Restitution is the first-line repair response, operating within minutes to hours after injury, before the slower processes of proliferation and differentiation take effect.
-
Mucus gel modification: TFF3 homodimers cross-link mucin glycoproteins (principally MUC2 in the intestine), increasing the viscosity and cohesiveness of the mucus gel layer. This strengthens the physical barrier separating epithelial cells from luminal bacteria and digestive enzymes. Thim et al. (2002) demonstrated that TFF3 dimers increase mucus viscosity in a concentration-dependent manner.
-
Anti-apoptotic activity: TFF3 activates the PI3K/Akt survival pathway in intestinal epithelial cells, reducing apoptosis in response to cytokine injury, detachment (anoikis), and oxidative stress. This cytoprotective effect helps maintain epithelial barrier integrity during inflammatory insults.
-
EGFR transactivation: TFF3 signaling involves transactivation of the epidermal growth factor receptor (EGFR) and downstream ERK1/2 phosphorylation. This EGFR-dependent pathway is important for TFF3-mediated cell migration and survival, and links TFF3 biology to the broader EGF family signaling network.
-
Tight junction regulation: TFF3 enhances epithelial barrier function by promoting the expression and assembly of tight junction proteins, including claudins and ZO-1. This reduces paracellular permeability and bacterial translocation.
-
Immune modulation: TFF3 modulates mucosal immune responses by reducing pro-inflammatory cytokine expression (TNF-alpha, IL-1beta, IL-8) and promoting anti-inflammatory signaling, contributing to resolution of mucosal inflammation.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Neonatal Gut Protection
TFF3 is present in human breast milk and amniotic fluid, suggesting a role in neonatal gut maturation and protection. Premature infants, who lack mature goblet cells and produce insufficient TFF3 and mucus, are at high risk for necrotizing enterocolitis (NEC). Exogenous TFF3 supplementation reduces NEC severity in neonatal rat models, supporting the hypothesis that breast milk-derived trefoil factors contribute to NEC prevention.
Comparison with BPC-157 for Gut Healing
Both TFF3 and BPC-157 promote gastrointestinal mucosal healing, but through distinct mechanisms. BPC-157 acts primarily through angiogenic pathways (VEGFR2 upregulation, NO system modulation) and stimulates fibroblast migration and extracellular matrix deposition. TFF3, by contrast, operates at the epithelial surface through motogenic signaling (rapid cell migration) and mucus gel modification. BPC-157 is stable in gastric acid and effective orally; TFF3 is protease-resistant but requires formulation optimization for oral delivery. In experimental colitis models, both peptides reduce injury scores and accelerate healing, though they have not been directly compared in head-to-head studies. Their complementary mechanisms — BPC-157 promoting vascular repair and deep tissue healing, TFF3 promoting epithelial restitution and mucus barrier restoration — suggest potential synergy.
Mucosal Restitution and Wound Healing
The defining biological activity of TFF3 is its ability to promote rapid restitution of wounded intestinal epithelium. In vitro wound closure assays using intestinal epithelial cell monolayers (IEC-6, Caco-2, HT-29) demonstrate that recombinant TFF3 accelerates wound closure by 2-4 fold, an effect that is blocked by anti-TFF3 antibodies, PI3K inhibitors, and MEK inhibitors. In vivo, TFF3 administration (oral or rectal) reduces mucosal injury scores and accelerates healing in acetic acid-induced colitis, DSS colitis, and indomethacin-induced small intestinal injury. Mashimo et al. (1996) demonstrated that TFF3 knockout mice are hypersensitive to DSS-induced colitis, developing severe mucosal injury and dying at doses that produce only mild, self-limiting colitis in wild-type animals, establishing TFF3 as a critical endogenous protective factor.
Goblet Cell Biology and Co-secretion with Mucins
TFF3 is co-stored with MUC2 in goblet cell secretory granules and is released by compound exocytosis in response to cholinergic stimulation, luminal irritants, and inflammatory mediators. The co-secretion ensures that TFF3 is delivered precisely where it is needed — embedded within the protective mucus blanket. Studies using transgenic mice with selective goblet cell ablation (Math1 knockout, Muc2 knockout) show that loss of goblet cells and their TFF3/MUC2 cargo produces spontaneous colitis, confirming the functional partnership between TFF3 and mucins in mucosal defense. Van der Sluis et al. (2006) showed that Muc2-deficient mice develop spontaneous colitis resembling human ulcerative colitis.
Inflammatory Bowel Disease
TFF3 expression is altered in inflammatory bowel disease (IBD). In ulcerative colitis, goblet cell depletion reduces TFF3 availability at inflamed mucosal surfaces, potentially exacerbating epithelial barrier dysfunction. Conversely, TFF3 is upregulated in the ulcer-associated cell lineage (UACL) at margins of Crohn's disease ulcers, representing an adaptive repair response. Recombinant TFF3 administration reduces colitis severity in multiple animal models, including TNBS-induced colitis and IL-10 knockout spontaneous colitis. Clinical development of TFF3 for IBD has been limited by delivery challenges (oral bioavailability of the peptide) and the development of TFF3-Fc fusion proteins intended to extend the half-life and improve systemic exposure.
TFF3-Fc Fusion Proteins
To overcome the short and variable half-life of native TFF3, researchers have developed TFF3-Fc fusion proteins — recombinant constructs that link TFF3 to the Fc fragment of IgG1. These fusion proteins retain TFF3 bioactivity while gaining the extended serum half-life (~21 days) conferred by FcRn-mediated recycling. Belle et al. (2020) demonstrated that TFF3-Fc fusion protein protects against DSS colitis in mice with superior efficacy and duration compared to unmodified TFF3. These constructs are in preclinical development as potential therapeutics for IBD and short bowel syndrome.
Safety Profile
TFF3 is an endogenous peptide constitutively secreted in large quantities by goblet cells throughout the intestinal tract, and recombinant TFF3 has shown no evidence of toxicity in preclinical studies at doses many-fold above physiological levels. No organ toxicity, mutagenicity, or immunogenicity has been observed in rodent and porcine models. The principal theoretical concern relates to TFF3's motogenic and anti-apoptotic activities — properties that could theoretically promote tumor cell migration or survival. TFF3 is overexpressed in certain cancers (breast, hepatocellular, pancreatic), where it has been associated with increased invasiveness and metastatic potential. However, in the normal intestine, TFF3 appears to play a tumor-suppressive role by maintaining mucosal integrity and reducing chronic inflammation, a major driver of colorectal carcinogenesis.
Recombinant TFF3 has not yet entered formal human clinical trials, and no standardized dosing regimen has been established. Preclinical studies have used doses ranging from 0.1-10 mg/kg administered orally or rectally, with consistent efficacy and no adverse effects. Oral formulations face challenges related to variable gastric transit and luminal dilution, though TFF3's intrinsic protease resistance mitigates concerns about enzymatic degradation.
Pharmacokinetic Profile
- Half-life
- Variable (oral formulations in development)
Quick Start
- Route
- Oral, rectal
Molecular Structure
- Formula
- C₂₉₅H₄₅₃N₇₉O₉₃S₇
- CAS
- 181289-28-1
Research Protocols
oral
In vivo, TFF3 administration (oral or rectal) reduces mucosal injury scores and accelerates healing in acetic acid-induced colitis, DSS colitis, and indomethacin-induced small intestinal injury. Clinical development of TFF3 for IBD has been limited by delivery challenges (oral bioavailability of the
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 0.1-10 mg | Per protocol | —(Route: Oral) |
Interactions
Peptide Interactions
Both TFF3 and BPC-157 promote gastrointestinal mucosal healing, but through distinct mechanisms. BPC-157 acts primarily through angiogenic pathways (VEGFR2 upregulation, NO system modulation) and stimulates fibroblast migration and extracellular matrix deposition. TFF3, by contrast, operates at t...
Their complementary mechanisms — BPC-157 promoting vascular repair and deep tissue healing, TFF3 promoting epithelial restitution and mucus barrier restoration — suggest potential synergy.
Quality Indicators
What to look for
- Human clinical trials conducted
- Extensive peer-reviewed research base
- Oral administration available
Red flags
- Potential carcinogenicity concerns
Frequently Asked Questions
References (16)
- [10]
- [7]
- [8]
- [9]
- [1]Mashimo H et al Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor (1996)
- [2]
- [3]
- [4]
- [5]
- [6]Belle NM et al TFF3-Fc fusion protein protects against intestinal mucosal injury in experimental colitis (2020)
- [11]
- [12]
- [13]**Belle et al ** developed a PEGylated TFF3 dimer with 40-fold extended serum half-life that demonstrated dose-dependent mucosal protection in chronic DSS colitis and radiation-induced intestinal injury models, advancing toward IND-enabling studies Belle et al. (2022) (2022)
- [14]**Zhang et al ** identified TFF3 as a key goblet cell-derived factor that reprograms intestinal stem cells toward secretory lineage differentiation following mucosal injury, revealing a previously unknown role for TFF3 in stem cell niche regulation Zhang et al. (2023) (2023)
- [15]**Hoffmann et al ** demonstrated that TFF3 deficiency in human intestinal organoids leads to loss of mucus barrier coherence and increased bacterial penetration, confirming the cross-linking function of TFF3 dimers in human tissue Hoffmann et al. (2024) (2024)
- [16]**Aihara et al ** reported that recombinant TFF3 delivered via pH-responsive nanoparticles achieved targeted ileal release and reduced intestinal permeability in a porcine model of gut barrier dysfunction, establishing feasibility for oral TFF3 therapy Aihara et al. (2023) (2023)
Insulin-Like Peptide 3 (INSL3)
INSL3 (Relaxin-Like Factor) is a two-chain peptide hormone produced primarily by Leydig cells in the testes and theca cells in the ovary. It serves as a critical biomarker of Leydig cell function and plays key roles in testicular descent, bone metabolism, and reproductive physiology through activation of the RXFP2 receptor.
IPA Blend (CJC-1295 / Ipamorelin)
A research peptide blend combining CJC-1295 (Mod GRF 1-29, 5mg) with Ipamorelin (10mg), pairing a GHRH analogue with a selective ghrelin receptor agonist for synergistic pulsatile growth hormone release through dual-receptor activation on pituitary somatotrophs.